NL-OMON42306已完成不适用
Myeloid and plasmacytoid blood dendritic cells for immunotherapy of stage III melanoma patients - myDC/pDC in stage III melanoma patients
Tumor Immunologie0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- stage III melanoma according to the 2009 AJCC criteria
- •- cytological or histological documented evidence of stage III melanoma
- •- WHO performance status 0-1 (Karnofsky 100-70) (Appendix 1)
- •- life expectancy *3 months
- •- age 18-75 years
- •- WBC >3.0×109/l, lymphocytes >0.8×109/l, platelets >100×109/l,
- •serum creatinine <150 µmol/l, serum bilirubin <25 µmol/l
- •- normal serum LDH (*250 U/l)
- •- expected adequacy of follow-up
- •- no pregnant or lactating women
- •- written informed consent
排除标准
- •- irresectable stage III melanoma or stage IV melanoma
- •- any concurrent adjuvant therapy
- •- history of any second malignancy in the previous 5 years, with the exception of adequately treated basal cell carcinoma or carcinoma in situ of the cervix
- •- serious active infections, known HbsAg or HIV positive, or autoimmune diseases or organ allografts
- •- concomitant use of oral immunosuppressive drugs
- •- known allergy to shell fish (since it contains KLH)
- •- any serious clinical condition that may interfere with the safe administration of DC or apheresis
研究者
相似试验
进行中（未招募）
1 期
Vaccination with dendritic cells (DC) obtained from blood and loaded with fluorine particles and proteins derived from tumor cells of patients with stage III melanoma in whom a radical lymph node dissection is planned, and visualization of migration in vivomelanoma patients with regional lymph node metastases (stage III)EUCTR2010-023757-11-NLRadboud University Nijmegen Medical Centre28
尚未招募
不适用
Analysis of Dendritic cells in blood and focal area in patients with refractory inflammatory diseasesRefractory inflammatory disease (interstitial pneumonia, bronchial asthma, Crohn's disease, ulcerative colitis, Behcet's disease)JPRN-UMIN000017035Kansai Medical University, First Dept. Internal Medicine40
已完成
不适用
Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) in metastatic pancreatic disease (REACtiVe-2 Trial)NL-OMON52234Erasmus MC, Universitair Medisch Centrum Rotterdam30
招募中
不适用
Dendritic Cells loaded with allogeneic tumor lysate (MesoPher) in combination with a CD40 agonist (Mitazalimab) in metastatic pancreatic diseaseNL-OMON27591Department of Pulmonary Medicine, Erasmus MC18
招募中
不适用
Importance of dendritic cells in pathogenesis and therapy of conjunctival melanomaC69.0ConjunctivaDRKS00016901niversitätsaugenklinik Köln50